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Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. 
Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft- 
versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoi-
etic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. 
We assessed adverse events and safety using DSCs among 44 treated patients and 40 
controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 106 DSCs/kg. The 
patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months 
after the last DSC infusion. Three patients had transient reactions during DSC infusion. 
Laboratory values, hemorrhages, and transfusions were similar in the two groups. The 
frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) 
were the same in the two groups. Causes of death were those seen in HSCT patients: 
infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), 
multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC 
patients with GVHD was 67%, which was significantly better than achieved previously 
at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions 
appear safe. Randomized studies are required to prove efficacy.
Keywords: graft-versus-host disease, mesenchymal stromal cells, hematopoietic stem cell transplantation, 
hemorrhagic cystitis, decidual stromal cells
inTrODUcTiOn
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic 
hematopoietic stem cell transplantation (HSCT) (1, 2). Acute GVHD is caused by donor cytotoxic 
T cell activation against specific recipient histocompatibility antigens (3). There is no specific therapy 
for severe acute GVHD and the outcome is dismal for severe or steroid refractory disease (4–6).
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Hemorrhagic cystitis (HC) is a toxic complication after 
HSCT that may be caused by the conditioning (7). Mesenchymal 
stromal cells (MSCs) have a multilineage differentiation and 
immunomodulatory capacity (8–10). We introduced MSCs as 
a novel modulatory therapy for acute GVHD and tissue toxicity 
such as HC after HSCT (11–13). Efficacy of MSC for treatment 
of acute GVHD was confirmed in several studies (14). The 
outcome using MSCs for acute GVHD in a long-term follow-
up and in partial responders and non-responders was poor 
(15, 16). MSCs were given to 23 patients with severe acute 
GVHD between 2001 and 2007 in pilot studies (11, 12, 15, 16). 
In a randomized double-blind study, 12 patients were given 
MSCs and 11 were given placebo for acute GVHD between 
2007 and 2010 (unpublished data). There was no difference in 
survival between the two groups. Therefore, it was of interest 
to investigate immunomodulatory effects of other sources of 
stromal cells (17, 18).
The placenta protects the fetus from the mother’s immune 
system during pregnancy and provides a readily available source 
of stromal cells (19, 20). There is over 100 years of experience of 
using the placenta to successfully treat burn injuries in Africa 
(20). These finding and a potentially unlimited supply inspired 
us to use placental stromal cells for immunosuppression in 
experimental and clinical trials (20–23). We have isolated 
stromal cells from the fetal membrane of maternal origin, the 
so-called decidual stromal cells (DSCs). DSCs inhibit alloreac-
tive T  cell proliferation better than other sources of stromal 
cells (20). Although surface markers are the same, DSCs 
differ from other sources of MSCs, especially bone marrow 
(BM-MSC), in several aspects (20, 21). DSCs are half the size 
of BM-MSCs, they need direct contact to be immunosuppres-
sive in  vitro, have a better expansion capacity, and seem to 
tolerate freeze-thawing better (21–24). Like MSCs, third party 
DSCs are immunosuppressive in vitro and in vivo (11, 12, 15, 
21, 25). DSCs suppressed the production of interferon gamma 
and interleukin 17 and increased IL-10 in mixed lymphocyte 
cultures (MLC) as opposed to BM-MSCs that had no effect on 
these cytokines (20).
BM-MSCs have been proven safe in a large number of stud-
ies (26, 27). Because DSCs differ from BM-MSCs, we wanted to 
evaluate safety and side effects. Like MSCs, DSCs affect coagula-
tion and can stop hemorrhages (23). Because of the procoagulant 
activities of DSCs and BM-MSCs, thromboembolism was looked 
for as potential side effects.
MaTerials anD MeThODs
Patients and ethics
The study included 44 patients, treated from February 2011 to 
October 2014, with acute GVHD (n = 34) or HC (n = 10) and 
40 controls, 30 with acute GVHD and 10 with HC, treated from 
August 2003 to May 2014. We obtained ethical approval from 
Karolinska Institutet to collect stromal cells from placentas after 
cesarean sections (2009/418-31/4) and to use DSCs clinically for 
tissue toxicity, hemorrhaging, and grades II–IV acute GVHD 
after HSCT (2010/452-31/4).
Preparation of Dscs
After obtaining informed consent, the DSCs were harvested 
from nine different human term placentas obtained from healthy 
mothers according to an earlier protocol during elective 
cesarean-section births (21). Using flow cytometry, the DSCs 
were positive for CD29, CD44, CD74, CD90, CD105, CD49d, 
PD-L1, PD-L2, ICAM-1, and HLA-1. They were negative for 
CD11a, CD14, CD18, CD31, CD34, CD45, CD85, HLA-G, 
SSEA-3, SSEA-4, CXCR4, VCAM, EpCAM-1, and HLA-2. All 
DSCs showed normal karyotype. All donors were seronega-
tive for HIV, hepatitis A and B, and syphilis. The DSCs from 
the various placentas were tested for their capacity to inhibit 
MLC (20, 21).
infusion of cells
After expansion of the cells to second to fourth passage, the 
cells were frozen slowly in Dulbecco’s modified eagles medium 
(Thermo-Fisher Scientific) containing 10% dimethyl sulfoxide 
(WAK-Chemie Medical GmbH, Steinbach, German7). The cells 
were thawed at 37°C and washed in CliniMACS PBSEDTA buffer 
(AmCell Miltenyi Biotec GmbH, Gladbach, Germany) supple-
mented with either 10% AB-plasma (18 patients) or 5% albumin 
(CSL Behring GmbH, Marburg, Germany) (25 patients). The cells 
were resuspended as above at a concentration of 2 ×  106 cells/
mL. The cell suspension was filtered through a 70-µm cell strainer 
(BD) before it was transferred to a heparinized syringe. All cell 
preparations were tested for bacterial contamination before 
freezing, and from the infusion suspension. DSCs were infused 
intravenously for 5 min via a central venous line. Before and after 
infusion of DSCs, 5  mL of saline with 12.5–50 IE heparin/mL 
(depending on weight of the patient) was infused. The patients 
were checked regularly for 2 h after infusion of the cells. Twenty-
one cell infusions were given with cells cultured to passage 2, 
31 with cells cultured to passage 3, and 30 with cells cultured 
to passage 4. The viability of infused cells was median 93% 
(range 69–99). The dose was 1.5 (0.9–2.9) × 106 viable DSCs/kg. 
Patients were given median 2 (range 1–5) doses with a total of 
82 infusions.
Patient characteristics
Patient characteristics are given in Table 1. Because we wanted to 
be able to compare laboratory values and adverse events, we tried 
to select patients who had survived at least 3 months. The GVHD 
controls were matched if possible with the DSC patients for age, 
donor (sibling versus unrelated), disease, disease stage, donor age, 
anti-thymocyte globulin (ATG) prophylaxis, donor–recipient 
sex match, conditioning, cell source, and partly survival after 
acute GVHD (Table 1). The control group was treated between 
2003 and 2014 and was selected among the most recent patients 
treated for severe acute GVHD and HC. The controls were not 
treated with DSCs or MSCs. Patients were treated with DSCs for 
severe acute GVHD, if they did not respond to steroids or they 
had co-morbidities and were thought not to tolerate long high-
dose steroid therapy. If response was not satisfactory, additional 
weekly doses were given.
TaBle 1 | Patient characteristics.
Factor Decidual stromal cell (Dsc)-graft-
versus-host disease (gVhD)
Dsc-hemorrhagic cystitis (hc) gVhD-c hc-c
N 34 10 30 10
Age, median (range) 49 (1–68) 43.5 (8–50) 49 (4–63) 35.5 (16–59)
All DSC patients = 48.5 (1–68) All controls = 48 (4–63)
Children (<18 years) 6 1 5 2
Sex (M/F) 20/14 4/6 17/13 10
Diagnosis:
Non-malignant 4 1 0 0
Acute leukemia 10 6 8 10
Lymphoma 4 0 4 1
MDS 10 2 7 0
Chronic leukemia 2 1 5 1
Other 4 0 6 0
Disease stage (E/L) 12/22 6/4 6/18 7/5
Donor:
MRD 13 2 12 1
MUD 20 5 13 6
MM 1 3 5 5
Donor age, mean (range) 34 (0–68) 41 (0–58) 37 (0–63) 36 (0–55)
Female to male 7 1 6 3
conditioning:
TBI-based 12 1 7 4
Chemo-based 22 9 23 8
MAC/RIC 12/22 9/1 11/19 9/3
ATG 21 9 20 10
sc source:
BM/PBSCs/CB 9/24/1 2/7/1 2/24/4 1/9/2
TNC dose, mean (range) 7.6 (1.3–24.5) 7.7 (0.4–25) 10.6 (0.3–21.0) 8.1 (0.3–15.6)
CD34 dose, mean (range) 6.5 (0.2–14.2) 6.3 (0.1–9.7) 9.8 (0.1–18.8) 4.9 (0.1–9.7)
gVhD prophylaxis:
CsA + MTX 22 9 23 8
Prograf + Sirolimus 11 0 3 2
CsA + Prednisolon 0 1 4 1
HD Cy post SCT 1 0 0 1
G-CSF post hematopoietic stem cell transplantation 7 1 3 7
Bacteremia 10 6 8 8
IFIs 4 2 4 2
acute gVhD
0 0 4 0 4
I 0 2 0 2
II 13 3 0 5
III–IV 21 1 30 1
Hemorr. cystitis ≥ II 4 10 4 10
MRD, matched related donor; MUD, matched unrelated donor; MM, mismatched donor; Female to male, number of male recipients with female donors; TBI, total body irradiation; 
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; ATG, anti-thymocyte globulin; BM, bone marrow; PBSCs, peripheral blood stem cells; CB, umbilical cord 
blood stem cells; TNC, total nucleated cell; CSA, cyclosporine; MTX, methotrexate; HD Cy, high-dose cyclophosphamide; G-CSF, granulocyte colony stimulating factor; IFIs, 
invasive fungal infections; Disease stage, Early (E), first complete remission or first chronic phase, leukemia or non-malignant disease. All other stages were considered late (L); 
MDS, myelodysplastic syndrome, MDS refractory anemia with ringed sideroblasts, and unspecified MDS with <5% marrow blasts. Late refers to all other disease stages.
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conditioning and gVhD Prophylaxis
Myeloablative conditioning before HSCT was cyclophospha-
mide (120 mg/kg) combined with 12 Gy fractionated total body 
irradiation (TBI) or oral busulfan (16  mg/kg) (28). Reduced-
intensity conditioning consisted of fludarabine (30 mg/kg/day) 
for 3–5  days combined with busulfan (8  mg/kg), treosulfan 
(36 mg/kg), and for lymphoma patients, also TBI as previously 
described (29). GVHD prophylaxis was mainly cyclosporine 
and four doses of methotrexate (30), or sirolimus and tacrolimus 
(31, 32). Recipients of hematopoietic cord blood grafts (n = 8) 
were given cyclosporine combined with prednisolone (33).
supportive care
Patients were treated in reversed isolation in hospital, or at home 
as previously described (34). Infection prophylaxis and other 
support have already been published in detail (32–36).
Diagnosis and Treatment of gVhD
Acute GVHD was diagnosed and staged according to the Seattle 
criteria (37). In patients with diarrhea, colonoscopy and biopsies 
were performed. Patients with acute GVHD, who did not respond 
to prednisolone, were given ATG or daclizumab combined with 
rituximab as second-line treatment. Extracorporeal psoralene 
4Baygan et al. Side Effects of DSCs
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and ultraviolet type-A was given as third-line therapy in some 
patients. Sometimes other immunosuppressive drugs were used 
if no response was seen, as described previously (35). After the 
introduction of MSCs, patients who were not responding to 
prednisolone were initially given MSCs, but more recently they 
were given DSCs (11, 12, 21).
hemorrhagic cystitis
Patients with HC were treated with Misoprostrol (a prostaglan-
dine analog), given 3 mg three times a day and forced diuresis if 
required, and they were classified according to published criteria 
(7). Persistent HC was treated with BM-MSCs or DSCs (13, 38).
Data collection
The medical records were read in full, starting from 3 days before 
DSC infusion and continuing up to 93 days after the last DSC 
infusion. For the controls, the date of onset of acute GVHD or 
HC plus 13 days was used as day 0, since 13 days was the median 
amount of days for DSC-treated patients to receive DSCs after the 
diagnosis of acute GVHD or HC.
laboratory and Vital Data
The parameters analyzed were as follows: blood hemoglobin 
(g/L), blood leukocytes and neutrophils (counts/L), blood 
thrombocytes (counts/L), C-reactive peptide (mg/L), aspartate 
aminotransferase (ASAT; μkat/L), alanine aminotransferase 
(ALAT; μkat/L), serum albumin (g/L), serum bilirubin (μmol/L), 
S-potassium (mmol/L), S-creatinine (μmol/L), S-calcium 
(mmol/L), S-free calcium/ionized calcium (mmol/L), systolic 
blood pressure (mmHg), and body temperature (°C).
The time intervals chosen for assessment were “before infu-
sion” (0–3 days before infusion), “after infusion” (0–3 days after 
infusion), “1, 2, 3, and 4 weeks after infusion.”
adverse events
All adverse events from the patient records were noted and then 
sorted into these categories: acute coronary syndrome, stroke/
transient ischemic attack, pulmonary or arterial thrombosis, 
venous thrombosis, disability, diarrhea, neutropenia, fever, and 
death. An event of thromboembolic disease or stroke needed to 
be confirmed using computed tomography or ultrasonography. 
Disability was divided into five separate categories in order to eas-
ily recognize differences between the patient groups: (1) patient 
requiring oxygenation, (2) muscular cramps, (3) any reduction 
in mobility, (4) any episode of confusion, hallucinations, or 
unconsciousness, and (5) sedation. Fever was defined above 
38°C and neutropenia as a neutrophil count below 0.5 × 109/L. 
Mucositis was diagnosed according to WHO criteria (WHO and 
Book for Reporting Results for Cancer Treatment, Geneva: World 
Health Organization 1979) (39), patients were categorized only in 
control and DSC groups for this analysis. The relative frequency 
of diarrhea, nausea, vomiting, fever, mucositis, and disability in 
the groups was compared by calculating the proportion of days 
these symptoms occurred for each patient.
infections
Any occurrence of infections was monitored, examining micro-
biological, radiological, and clinical data from the medical journals 
at any given time. Virus titers for Herpes Simplex Virus (HSV), 
adenovirus, Epstein–Barr virus, Varicella-Zoster virus (VZV), and 
cytomegalovirus (CMV) reactivation were continuously assessed 
using PCR (40). CMV disease was a symptomatic infection. Invasive 
fungal infection was diagnosed as either proven or probable (41).
statistics
Overall survival was calculated using the Kaplan–Meier method. 
The Mann–Whitney U test was used to compare continuous 
variables such as age, oral mucositis as well as laboratory, and 
vital data. Categorical variables were compared using Fisher’s 
exact test. Three hundred and fourty tests were performed which 
means that 17 tests were expected to be significant at the 5% level 
by chance. Four tests may be significant at random at the 1% level. 
Analyses were performed using the Statistica software (Statsoft, 
Tulsa, MN, USA).
Frequency of adverse events was compared using descriptive 
statistics, p-values were calculated along with 95% confidence 
interval using GraphPad Prism software (San Diego, CA, USA). 
Mean patient age was compared using unpaired two-sided t-test. 
Occurrence of infectious diseases and fungal prophylaxis were 
compared using Fisher’s exact test.
resUlTs
Data collection and Patient age
The follow-up time for laboratory values was significantly longer in 
the DSC-treated group, median 94 days (range 5–235), than in the 
controls, median 94 (1–94) (p = 0.047). There were no statistically 
significant differences in age, diagnosis, stem cell source, propor-
tion of female donor to male recipients, conditioning, or GVHD 
prophylaxis between the DSC and the control groups (Table 1).
infusion-related adverse reactions
Three patients experienced symptoms associated with infusion 
of DSCs.
A male transplanted for follicular lymphoma received five 
DSC infusions for acute GVHD. He experienced fever and chills 
during the first infusion. He had an ongoing Staphylococcus 
epidermidis sepsis. No negative reactions were observed during 
the subsequent four DSC infusions that were given 7, 14, 18, and 
169 days after the first DSC infusion.
A child was transplanted for pre-B acute lymphoblastic leu-
kemia and received five DSC infusions. During the fourth DSC 
infusion, the patient experienced headache and dyspnea, and the 
oxygen saturation dropped to 83%. This was remedied by giving 
him oxygen support. Before the fifth infusion, he experienced 
anxiety and was given oxygen support before and during the 
infusion to counteract this, and the infusion proceeded without 
any problems.
A male, transplanted for sickle-cell anemia, experienced 
transient vertigo during the cell infusion. The patients did not 
experience vertigo thereafter.
laboratory Data and Vital Data
There were no significant differences in blood leukocyte counts, 
C-reactive protein, ASAT, ALAT, creatinine, or bound and free 
calcium. Hemoglobin, bilirubin, platelet, and albumin levels 
TaBle 3 | Significant findings in frequency of cytomegalovirus (CMV) 








Proportion 0.749 0.698 0.792 0.683 0.612 0.725
N (Serum assays) 506 311 393 218 125 109
p-Value 0.123 0.005 0.093
non-invasive fungal infections
N (patients) 6 14 5 10 1 4
p-Value 0.039 0.1379 0.303
Posaconazole prophylaxis
Proportion 0.516 0.273 0.551 0.303 0.389 0.194
N (days) 4,128 2,814 3,285 2,017 890 797
p-Value <0.0001 <0.0001 <0.0001
P. jirovecii prophylaxis
Proportion 0.853 0.865 0.842 0.822 0.896 0.971
N (days) 4,128 2,854 3,285 2,187 890 837
p-Value 0.163 0.057 <0.0001
Numbers in bold indicate statistical significance. DSC, decidual stromal cell treated 
group (n = 44); DSC-GVHD, decidual stromal cell treated graft-versus-host disease 
group (n = 34); DSC-HC, decidual stromal cell treated hemorrhagic cystitis group 
(n = 10); CTRL, controls (n = 40); CTRL-GVHD, graft-versus-host control group 
(n = 30); CTRL-HC, hemorrhagic cystitis control group (n = 10). “Difference” indicates 
the 95% CI of the difference between the groups, p-value calculated using two-sided 
t-test. The “proportion” value indicates the proportion of positive serum assays for 
CMV-PCR positivity and the proportion of days with prophylactic therapy. p-Value 
calculated using Fisher’s exact test.
TaBle 2 | Hemoglobin, platelet, albumin, and bilirubin levels.








Median Median Median Median Median Median
hemoglobin
DSC 103.5 99.5 100 104 106 108
CTRL 106 110 107 113.5 107.5 103.5
DSC-GVHD 110 101 102 106 106 109.5
CTRL-GVHD 109 111 109 114 110.5 102
Thrombocytes
DSC 81 65.5 63.5 59 56.5 68
CTRL 47 52 68 47.5 49 64
DSC-GVHD 78 65 56 47 54.5 61
CTRL-GVHD 70 61 74 56 42.5 64
albumin
DSC 25 22 26 28 29.5 30
CTRL 28 27 26 28 26 28.5
DSC-GVHD 25 22 26 28 28.5 29
CTRL-GVHD 27 24 23.5 24 24 24
Bilirubin
DSC 9 10.5 10 10 9.5 8
CTRL 13 14 14.5 12.5 14 13
DSC-GVHD 9 12 11 12 10 9.5
CTRL-GVHD 15.5 25.5 17 15 18 17
DSC, decidual stromal cell treated group (n = 44); CTRL, controls (n = 40); DSC-
GVHD, decidual stromal cell treated graft-versus-host disease group (n = 34); CTRL-
GVHD, graft-versus-host control group (n = 30).
Numbers in bold indicate statistical significance using Mann-Whitney U test.
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are presented in Table 2. The controls with GVHD had higher 
hemoglobin levels than the DSC group at 2  weeks after day 0. 
Three weeks after day 0, albumin levels were significantly higher 
in the acute GVHD group treated with DSCs than in the acute 
GVHD-control group (p =  0.03). Bilirubin levels were higher 
in the GVHD-control group than in the DSC patients, before 
infusion of DSCs. Platelet counts were not significantly different 
between any compared groups.
adverse events, infections, relapse of 
Malignant Disease, and causes of Death
On day 0, the median WHO mucositis score was 2 (range 0–3) 
in all DSC patients and 2 (range 0–3) in the controls (p = 0.659). 
There were no significant differences in mucositis score between 
the groups during the healing phase, to day 12.
Cytomegalovirus reactivation was more common in the con-
trols (p = 0.005, Table 3). There was no difference in the frequency 
of infections, such as pneumonia, septicemia, viral infections, 
or urinary tract infections. The DSC group had a higher mean 
prophylactic coverage against invasive fungal infections (IFIs) 
(Table 3).
Invasive fungal infection was observed in six of the DSC 
patients and six of the controls (Table 4). In the DSC group, 
there were three probable Aspergillus infections, one prob-
able and two proven zygomyzetes infections (one Rhizopus 
microsporus and one Rhizopus arrhizus). Among the controls 
were two probable Aspergillus infections, one probable and 
one proven mold infection, and two probable zygomyzetes 
infections. One of the latter later grew out Lichtheimia 
corymbifera.
Acute GVHD/HC DSC-treated patients had the following 
events: HSV reactivation; 8/3, CMV reactivation; 22/6, CMV 
disease; 5/3, VZV reactivation; 8/3, posttransplant lymphoprolif-
erative disorder; 0/0, IFIs 6/0, septicemia; 10/3, pneumonia; 6/1, 
and leukemic relapse; 2/0.
There were no significant differences between the DSC group 
and the controls concerning leukemic relapse or cause of death 
(Table 4).
Thromboembolism, stroke, and Transient 
ischemic attack
Four patients in the DSC-treated group and two in the control 
group had an adverse event with thromboembolism, stroke, 
or transient ischemic attack during the observation period 
(p = 0.678). Two DSC-treated patients and one control had had 
thromboembolic disease in the same location before the observa-
tion period. The two remaining DSC patients had IFIs.
A female patient transplanted for chronic myelomonocytic 
leukemia received two DSC doses for acute GVHD. A CT scan 
of the head and brain showed a suspected bleeding in the basal 
frontal region of the brain 45 days after the second DSC infusion. 
She had probable Aspergillus infections. The patient was alive 
during the 155 days observational period, but died later.
A female patient transplanted for pre-B acute lymphoblastic 
leukemia received four DSC doses for acute GVHD. The patient 
had a CT diagnosed subarachnoid bleeding and died 5 days after the 










2 2 2 0 0 2
p-Value 1.000 0.474 0.474
invasive fungal infections
6 6 6 4 0 2
p-Value
cause of death during observational period (n)
Infection 5 3 4 2 1 1
p-Value 0.467 0.676 1.000
Other/GVHD 2 7 2 6 0 1
p-Value 0.079 0.139 1.000
Respiratory failure 1 1 1 1 0 0
p-Value 1.000 1.000 1.000
Circulatory failure 3 1 3 1 0 0
p-Value 0.618 0.616 1.000
Thromboembolism 1a 0 1 0 0 0
p-Value 1.000 1.000 1.000
Multiple organ failure 0 1 0 1 0 0
p-Value 0.476 0.469 1.000
Numbers indicate number of patients. Numbers in bold indicate statistical significance. 
DSC, decidual stromal cell treated group (n = 44); DSC-GVHD, decidual stromal 
cell treated graft-versus-host disease group (n = 34); DSC-HC, decidual stromal cell 
treated hemorrhagic cystitis group (n = 10); CTRL, controls (n = 40); CTRL-GVHD, 
graft-versus-host control group (n = 30); CTRL-HC, hemorrhagic cystitis  
control group (n = 10).
aIn this case, the thromboembolism was a brain infarction.
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fourth DSC infusion. She had proven rhizopus fungal pneumonia. 
The patient had an observational period of 115 days with posa-
conazole prophylaxis during 93 days.
A male control patient transplanted for metastatic renal cell 
carcinoma had a thrombosis in the right popliteal vein on the 
65th day of observation.
hemorrhage and Transfusions
Hemorrhaging other than HC was seen in 36% of all DSC patients 
and in 40% of all controls (p = 0.82). The DSC patients requiring 
transfusions received a median of 9 (range 1–130) erythrocyte 
transfusions, as opposed to 8 (range 2–28) for the controls 
(p = 0.14). The corresponding figures for platelet transfusions in 
the two groups were 9 (range 1–74) and 9 (range 2–47), respec-
tively (p = 0.23).
survival
The probability of survival at 1 year was 67% in all acute GVHD 
patients treated with DSCs (Figure  1). Among patients with 
grade II and III–IV acute GVHD, the corresponding figures were 
92 and 52% in the two groups, respectively (Figure 2). One-year 
survival was 90% in the HC patients treated with DSCs (Figure 3).
DiscUssiOn
The data from this study suggest that DSCs are safe to use in the 
GVHD and HC settings, at the currently applied cell dose of 
1–3 × 106 DSCs/kg using low-dose heparin at infusion (21). The 
adverse events seen in these patients with severe acute GVHD and 
HSCT are commonly seen in patients with severe acute GVHD. 
Systolic blood pressure, body temperature, and serum albumin 
levels were higher at some time intervals in the DSC-treated 
patients compared to the controls, but they were never above 
normal range. There were no significant differences in severe 
adverse events or causes of death between the two groups. The 
causes of death were those usually seen in patients with GVHD 
or HC after HSCT (1, 2, 4–6).
With longer follow-up, some problems with BM-MSC treat-
ment have become apparent, such as increased risk of pneumonia 
(36), invasive fungal infection (16), posttransplant lymphopro-
liferative disease (42), and a decrease in immune reconstitution 
(43). However, many more patients will be required to find out 
whether or not any specific complication may be increased by 
treatment with DSCs. Serum albumin levels have been shown to 
be predictive of survival in patients with acute gastrointestinal 
GVHD (44) and the higher albumin levels seen in the DSC 
patients with GVHD may be a positive effect of DSC treatment.
In a previous study with a total of 99 BM-MSC infusions, 
two episodes of angina pectoris were reported in one patient 
(27). DSC infusion-related adverse reactions, including vertigo 
and reduced oxygen saturation, seemed to be closely associated 
with DSCs infusion. The patient who developed fever and chills 
during DSC infusion had an ongoing septicemia, so a role of DSC 
infusion in this case is less likely. A meta-analysis, including 1,012 
patients treated with MSCs, also showed that stromal cells are safe 
to infuse (26). In that study, there was a significant correlation 
between MSC infusion and transient fever. A slightly elevated 
fever was also observed in the DSC patients, compared to the 
controls.
Mesenchymal stromal cells and DSCs have the capacity to 
modulate the coagulation system and have, thus, been used to treat 
hemorrhaging (13, 38, 45). Even at early passages, DSCs express 
significantly higher levels of tissue factor than MSCs and, thus, 
warrant special preparation with low-dose heparin to minimize the 
potential risk for thromboembolism (45). Because DSCs and MSCs 
first home to the lung (46), pulmonary embolism should be looked 
for. The adverse reaction with reduced oxygen saturation during 
DSC infusion in one case, may be due to congestion with DSCs 
in the lung, rather than embolism formation. We did not see an 
increase in pulmonary embolism after DSC infusion. Pulmonary 
embolism has been reported after infusion with adipose-derived 
MSCs (47). Similarly, Acosta et al. documented two cases of periph-
eral microthrombosis upon application of adipose MSCs in two 
diabetic patients, associated with altered fibrinolytic activity (48). 
This was accompanied by increased levels of fibrinolysis marker 
D-dimer in venous blood. Elevated levels of D-dimer were also 
monitored by Stephenne et al., after systemic infusion of human 
adult liver progenitor cells (49), which could be antagonized by 
anti-thrombin therapy. We also found transiently increased levels 
of D-dimer shortly after infusion of DSCs with low-dose heparin, 
which rapidly dropped back to baseline levels, suggesting only 
minimal activation of innate immune cascades (45).
Anticipated adverse events after any immunosuppressive 
therapy, including DSCs, are increased risks of infections due 
FigUre 1 | Probability of survival among patients with acute graft-versus-host disease (GVHD) treated with decidual stromal cells (DSCs).
FigUre 2 | Probability of survival among patients with acute graft-versus-host disease grade II and III–IV respectively (GVHD) treated with decidual stromal cells (DSCs).
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to hampering of the immune recovery after HSCT. There was 
no difference in the frequency of IFIs between the groups. This 
may support the idea that DSCs do not increase the risk of IFIs. 
It should be noted that the DSC group had a different fungal 
prophylaxis coverage. In the earlier patients, ketoconazole or 
no fungal prophylaxis was used. In the more recent patients, 
posaconazole was given since this had recently become available. 
Further studies are needed to find out if this prophylaxis has 
FigUre 3 | Probability of survival among patients with hemorrhagic cystitis treated with decidual stromal cells.
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been effective or not. There is a report that MSCs gave a high 
incidence of IFIs after HSCT (16). Whether or not stromal cells 
affect immunity to fungi is now being investigated in mouse and 
pig models.
Cytomegalovirus reactivation was higher in the GVHD-
control group than in the DSC group. This difference was 
significant (p = 0.005) and may be important. It is possible that 
pharmacological immunosuppression given to the controls 
affected immunity to CMV much more than DSC therapy. This is 
supported by experimental data, which show that MSCs have not 
suppressed CMV-cytotoxic T-cells, while they suppress alloreac-
tive T-cells (50).
It is important to compare the results using DSCs with those 
using other immunosuppressive treatments for acute GVHD. 
Both groups were treated with cyclosporine and high doses of 
corticosteroids. The controls were also treated with a wide range 
of immunosuppressive drugs.
Safety was the objective of this study. Anyhow, survival in the 
GVHD and the HC groups seem promising using DSC, when 
compared to previous experience using other therapies at our 
unit (12, 18, 51). Patients with grade II acute GVHD had a bet-
ter survival probably because early therapy is of importance for 
outcome. It is also possible that some of these patients may have 
recovered with conventional therapy. One-year survival of 52% 
in the grade III–IV acute GVHD group is also promising. This is 
much better than what is reported in the literature (4–6).
There are some obvious advantages of using DSCs as opposed 
to other sources of stromal cells. There is an unlimited supply of 
placentas. The expansion rate is much higher (21), immunosup-
pressive capabilities may be higher because in  vitro in mixed 
lymphocyte culture DSC inhibition was more consistent than 
using BM-MSCs (20). Bone marrow aspiration is somewhat 
painful for the donor. For anti-inflammatory purposes, there is 
no need for differentiation to cartilage and bone which is one 
of the features of BM-MSCs (22). DSCs are only half the size 
of BM-MSCs so the risk of trapping in capillaries may be lower 
(23). One purpose of the placenta is to protect the fetus from 
the mother’s HLA-incompatible immune system. Therefore, 
immunosuppression is a major task for placental stromal cells.
The limitations of this study are obvious, it is not randomized, 
historic controls were used and the study was retrospective. 
Therefore, the data have to be taken with caution. We wanted to 
include controls to show which side effects are commonly seen in 
HSCT patients regardless of posttransplant therapy for severe 
acute GVHD. So far, we have not seen an increase of side effects 
using DSCs. There were only three adverse infusion reactions, 
and they were transient. The rates of malignant relapse and 
causes of death were similar in the DSC group and the controls. 
It should be noted that the follow-up for leukemic relapse 
was short. However, with more patients and longer follow-up, 
infections, leukemia relapse, chronic GVHD, and secondary 
malignancies, and other late problems after MSCT, need to be 
reevaluated.
Future directions include planning of randomized mul-
ticenter studies using DSCs compared to placebo for acute 
GVHD and HC, respectively, with early response as a primary 
endpoint. We also have ethical approval to explore DSCs for 
other inflammatory disorders such as inflammatory bowel dis-
ease, acute necrotizing pancreatitis, autoimmune inflammatory 
neurological disorders, and acute respiratory distress syndrome 
9Baygan et al. Side Effects of DSCs
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 795
reFerences
1. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle 
experience. Immunol Rev (1985) 88:215–38. doi:10.1111/j.1600-065X.1985.
tb01160.x 
2. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with 
HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. 
Transplantation (1985) 40:39–44. doi:10.1097/00007890-198507000-00009 
3. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, 
Schumacher TN, et  al. In situ dissection of the graft-versus-host activities 
of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 
(2002) 8:410–4. doi:10.1038/nm0402-410 
4. Deeg HJ. How I treat refractory acute GVHD. Blood (2007) 109(10):4119–26. 
doi:10.1182/blood-2006-12-041889 
5. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Quazilbash MH, 
et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 
(2015) 2011. doi:10.1155/2011/601953 
6. Martin PJ, Inamoto Y, Flowers ME, Carpenter PA. Secondary treatment of 
acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 
(2012) 18(7):982–8. doi:10.1016/j.bbmt.2012.04.006 
7. Potácová Z, Dalianis T, Le Blanc K, Ringdén O. Hemorrhagic cystitis. 2nd ed. In: 
Wingard  JR,  Gastineau  DA,  Leather  HL,  Snyder  EL,  Szczepiorkowski  ZM, 
editors. Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. 
(Chap. 34), Bethesda, MD: AABB (2015). p. 529–38.
8. Hoogduijn MJ, Popp FC, Grohnert A, Crop MJ, van Rhijn M, Eggenhofer E, 
et  al. Advancement of mesenchymal stem cell therapy in solid organ 
transplantation (MISOT). Transplantation (2010) 90:124–6. doi:10.1097/
TP.0b013e3181ea4240 
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. 
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 
284:43. doi:10.1126/science.284.5411.143 
10. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells. 
J Intern Med (2007) 2(62):509–25. doi:10.1111/j.1365-2796.2007.01844.x 
11. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, 
et  al. Treatment of severe acute graft-versus-host disease with third party 
haploidentical mesenchymal stem cells. Lancet (2004) 363:1439–41. 
doi:10.1016/S0140-6736(04)16104-7 
12. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, 
et  al. Mesenchymal stem cells for treatment of therapy-resistant graft-
versus-host disease. Transplantation (2006) 81:1390–7. doi:10.1097/01.
tp.0000214462.63943.14 
13. Ringdén O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J, et  al. 
Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cysti-
tis, pneumomediastinum and perforated colon. Leukemia (2007) 21:2271–6. 
doi:10.1038/sj.leu.2404833 
14. Hashmi S, Ahmed M, Murad H, Litzow MR, Adams RH, Ball LM, et  al. 
Survival after mesenchymal stromal cell therapy in steroid refractory acute 
graft-versus-host disease. A systematic review and meta-analysis. Lancet 
Haematol (2016) 3:e45–52. doi:10.1016/S2352-3026(15)00224-0 
15. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal 
stem cells for treatment of severe refractory acute graft-versus-host disease. 
Lancet (2008) 371:1579–86. doi:10.1016/S0140-6736(08)60690-X 
16. Remberger M, Ringdén O. Treatment of severe acute graft versus host dis-
ease with mesenchymal stromal cells: a comparison with non-MSC treated 
patients. Int J Hematol (2012) 96:822–4. doi:10.1007/s12185-012-1218-3 
17. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, et al. 
Adult human fibroblasts are potent immunoregulatory cells and functionally 
equivalent to mesenchymal stem cells. J Immunol (2007) 174:1595–604. 
doi:10.4049/jimmunol.179.3.1595 
18. Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, et al. Manufacturing 
of human placenta-derived mesenchymal stem cells for clinical trials. 
Br J Haematol (2009) 144(4):571–9. doi:10.1111/j.1365-2141.2008.07492.x 
19. In ‘t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, 
Claas FH, Fibbe WE, et  al. Isolation of mesenchymal stem cells of fetal or 
maternal origin from human placenta. Stem Cells (2004) 22(7):1338–45. 
doi:10.1634/stemcells.2004-0058 
20. Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, Ringdén O. Stromal 
cells from term fetal membrane are highly suppressive in allogeneic settings 
in  vitro. Clin Exp Immunol (2012) 167:543–55. doi:10.1111/j.1365-2249. 
2011.04540.x 
21. Ringdén O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, et al. Fetal 
membrane cells for treatment of steroid-refractory acute graft-versus-host 
disease. Stem Cells (2013) 31:592–601. doi:10.1002/stem.1314 
22. Erkers T, Nava S, Yosef J, Ringdén O, Kaipe H. Decidual stromal cells promote 
regulatory T  cells and suppress alloreactivity in a cell contact-dependent 
manner. Stem Cells Dev (2013) 22:2596–605. doi:10.1089/scd.2013.0079 
23. Moll G, Ignatowicz L, Catar R, Luecht C, Sadeghi B, Hamad O, et al. Different 
procoagulant activity of therapeutic mesenchymal stromal cells derived from 
bone marrow and placental decidua. Stem Cells Dev (2015) 24:2269–79. 
doi:10.1089/scd.2015.0120 
24. Hoogduijn MJ, de Witte SF, Luk F, van den Hout-van Vroonhoven MC, 
Ignatowicz L, Catar R, et  al. Effects of freeze-thawing and intravenous 
(ARDS). A patient with ARDS following HSCT was successfully 
cured by DSCs (52).
In conclusion, the data from this study, as a whole, do not 
indicate that DSC infusions would have a negative physiological 
effect on the patients, compared to other second- or third-line 
immunosuppressive drugs used for severe acute GVHD. DSCs 
also appeared to be safe in the HC patients. This study serves as 
a basis for future controlled, randomized trials to evaluate the 
efficacy of this novel therapy for acute GVHD and HC.
eThics sTaTeMenT
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki and in the case of minors written 
consent was given by their legal guardians. We obtained ethical 
approval from Regionala etikprövningsnämnden i Stockholm 
to collect stromal cells from placentas after caesarean sections 
(2009/418-31/4), and to use DSCs clinically for tissue toxicity, 
hemorrhaging, and grades II–IV acute GVHD after HSCT 
(2010/452-31/4).
aUThOr cOnTriBUTiOns
AB performed the data collection, categorical, and descriptive 
statistics. WA-K, GM, BT, BK, CH, and B-MS performed data 
collection. GD contributed to analysis of oral mucositis. LK 
performed the review of invasive fungal infections. BG and MW 
collected elective cesarean sections. MR performed statistical 
analysis on laboratory parameters. Everyone contributed to the 
writing.
acKnOWleDgMenTs
We thank Gunilla Tillinger for her preparation of this manu-
script. This work was supported by grants to or from the Swedish 
Cancer Society (CAN2013/671), the Swedish Research Council 
(K2014-64X-05971-34-4), the Children’s Cancer Foundation 
(PR2013-0045), the Cancer Society in Stockholm (111293), and 
Karolinska Institutet. GM’s contributions were made possible 
by DFG funding through the Berlin-Brandenburg School for 
Regenerative Therapies (BSRT, GSC203).
10
Baygan et al. Side Effects of DSCs
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 795
infusions of mesenchymal stromal cell gene expression. Stem Cell Rev (2016) 
25:586–97. doi:10.1089/scd.2015.0329 
25. Le Blanc K, Tammik C, Sundberg B, Haynesworth S, Ringdén O. Mesenchymal 
stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic 
responses independently of the major histocompatibility system. Scand 
J Immunol (2003) 57:11–20. doi:10.1046/j.1365-3083.2003.01176.x 
26. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, 
et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a sys-
tematic review and meta-analysis of clinical trials. PLoS One (2012) 7:e47559. 
doi:10.1371/journal.pone.0047559 
27. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, 
Parody R, Martínez C, et  al. Sequential third-party mesenchymal stromal 
cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow 
Transplant (2014) 20:1580–5. doi:10.1016/j.bbmt.2014.06.015 
28. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L, et al. 
A randomized trial comparing busulfan with total body irradiation as condi-
tioning in allogeneic marrow transplant recipients with leukemia: a report from 
the Nordic Bone Marrow Transplantation Group. Blood (1994) 83:2723–30. 
29. Ringdén O, Sadeghi B, Uzunel M, Solders M, Uhlin M, Mattsson J, et  al. 
Decreased risk of acute graft-versus-host disease using reduced intensity 
conditioning compared to myeloablative conditioning is independent of 
donor-recipient T-cell chimerism. J Transpl Technol Res (2014) 4(2):1000142. 
doi:10.4172/2161-0991.1000142 
30. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et  al. 
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis 
of graft-versus-host disease in patients given HLA-identical marrow grafts 
for leukemia: long-term follow-up of a controlled trial. Blood (1989) 73: 
1729–34. 
31. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, et al. Sirolimus and 
tacrolimus without methotrexate as graft-versus-host disease prophylaxis after 
matched related donor peripheral blood stem cell transplantation. Biol Blood 
Marrow Transplant (2004) 10:328–36. doi:10.1016/j.bbmt.2003.12.305 
32. Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, 
et al. A prospective randomized trial comparing cyclosporine/methotrexate 
and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after 
allogeneic hematopoietic stem cell transplantation. Hematologica (2016) 
101(11):1417–25. doi:10.3324/haematol.2016.149294 
33. Ringdén O, Okas M, Uhlin M, Uzunel M, Remberger M, Mattsson J. Unrelated 
cord blood and mismatched unrelated volunteer donor transplants, two alter-
natives in patients who lack an HLA-identical donor. Bone Marrow Transplant 
(2008) 42:643–8. doi:10.1038/bmt.2008.239 
34. Svahn BM, Remberger M, Myrbäck KE, Holmberg K, Eriksson B, Hentschke P, 
et al. Home care during the pancytopenic phase after allogeneic hematopoietic 
stem cell transplantation is advantageous compared with hospital care. Blood 
(2002) 100:4317–24. doi:10.1182/blood-2002-03-0801 
35. Ringdén O, Remberger M, Persson U, Ljungman P, Aldener A, Andström E, 
et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR 
identical unrelated bone marrow donors as with HLA-identical siblings. Bone 
Marrow Transplant (1995) 15:619–25. 
36. Forslöw U, Blennow O, LeBlanc K, Ringdén O, Gustafsson B, Mattsson J, et al. 
Treatment with mesenchymal stromal cells is a risk factor for pneumonia- 
related death after allogeneic hematopoietic stem cell transplantation. 
Eur J Haematol (2012) 89:220–7. doi:10.1111/j.1600-0609.2012.01824.x 
37. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et  al. 
Clinical manifestations of graft-versus-host disease in human recipients 
of marrow from HL-A-matched sibling donors. Transplantation (1974) 
18:295–304. doi:10.1097/00007890-197410000-00001 
38. Ringden O, Le Blanc K. Pooled MSCs for treatment of severe hemorrhage. 
Bone Marrow Transplant (2011) 46:1158–60. doi:10.1038/bmt.2010.262 
39. World Health Organization. WHO Handbook for Reporting Results for Cancer 
Treatment. Geneva: World Health Organization (1979).
40. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early 
occurrence of human cytomegalovirus infection after bone marrow 
transplantation as demonstrated by the polymerase chain reaction technique. 
Blood (1991) 77:1104–10. 
41. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. 
Revised definitions of invasive fungal disease from the European Organization 
for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative 
Group and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis (2008) 
46:1813–21. doi:10.1086/588660 
42. Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk 
factors for Epstein-Barr virus-related post-transplant lymphoproliferative dis-
ease after allogeneic hematopoietic stem cell transplantation. Haematologica 
(2014) 99:346–52. doi:10.3324/haematol.2013.087338 
43. Uhlin M, Sairafi D, Berglund S, Thunberg S, Gertow J, Ringden O, et  al. 
Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord 
blood transplantation. Stem Cells Dev (2012) 21:1409–17. doi:10.1089/
scd.2011.0310 
44. Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, et al. Serum 
albumin level predicts survival of patients with gastrointestinal acute graft-
versus-host disease after allogeneic stem cell transplantation. Ann Hematol 
(2014) 93:855–61. doi:10.1007/s00277-013-1957-0 
45. Moll G, Rasmusson-Duprez IR, von Bahr L, Andersen AMC, Sanchez J, 
Magnusson P, et  al. Are therapeutic human mesenchymal stromal cells 
compatible with human blood? Stem Cells (2012) 30:1565–74. doi:10.1002/
stem.1111 
46. Erkers T, Kaipe H, Nava S, Molldén P, Gustafsson B, Axelsson R, et  al. 
Treatment of severe chronic graft-versus-host disease with decidual stro-
mal cells and tracing with 111Indium radiolabeling. Stem Cells Dev (2015) 
24:253–63. doi:10.1089/scd.2014.0265 
47. Kaipe H, Erkers T, Sadeghi B, Ringden O. Stromal cells-are they really 
useful for GVHD? Bone Marrow Transplant (2014) 49:737–43. doi:10.1038/
bmt.2013.237 
48. Acosta L, Hmadcha A, Escacena N, Pérez-Camacho I, de la Cuesta A, 
Ruiz-Salmeron R, et  al. Adipose mesenchymal stromal cells isolated from 
type 2 diabetic patients display reduced fibrinolytic activity. Diabetes (2013) 
62:4266–9. doi:10.2337/db13-0896 
49. Stephenne X, Nicastro E, Eeckhoudt S, Hermans C, Nyabi O, Lombard C, et al. 
Bivalirudin in combination with heparin to control mesenchymal cell proco-
agulant activity. PLoS One (2012) 7:e42819. doi:10.1371/journal.pone.0042819 
50. Karlsson H, Samarasinghe S, Ball LM, Sundberg B, Lankester AC, Dazzi F, 
et  al. Mesenchymal stem cells exert differential effects on alloantigen and 
virus-specific T-cell responses. Blood (2008) 112:532–41. doi:10.1182/
blood-2007-10-119370 
51. von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, 
et al. Long-term complications, immunologic effects, and role of passage for 
outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 
(2012) 18:557–64. doi:10.1016/j.bbmt.2011.07.023 
52. Ringdén O, Solders M, Erkers T, Nava S, Molldén P, Hultcrantz M, 
et  al. Successful reversal of acute lung injury using placenta-de-
rived decidual stromal cells. J Stem Cell Res Therapy (2014) 4:244. 
doi:10.4172/2157-7633.1000244
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Baygan, Aronsson-Kurttila, Moretti, Tibert, Dahllöf, Klingspor, 
Gustafsson, Khoein, Moll, Hausmann, Svahn, Westgren, Remberger, Sadeghi and 
Ringden. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
